Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

STX-1150

Other · Acts on PCSK9

Phase 1 Most advanced trial
1 Registered trials

What is STX-1150?

STX-1150 is an investigational agent designed to epigenetically silence the PCSK9 gene without changing its underlying DNA sequence. It is being studied in elevated LDL-C and high cholesterol.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Targets
PCSK9
Mechanism
Acts on PCSK9
Pathways
epigenetic gene silencing
Therapy area
Cardiovascular, Metabolic
In trials of
SCTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07428473 Phase 1 Elevated LDL-C and High Cholesterol Recruiting SCTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Elevated LDL-C and High Cholesterol

Other drugs acting on PCSK9

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.